Analysts Set Kura Oncology, Inc. (NASDAQ:KURA) PT at $25.62

Kura Oncology, Inc. (NASDAQ:KURA) has earned an average rating of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and ten have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $25.40.

A number of equities research analysts have recently commented on KURA shares. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research report on Monday. Citizens Jmp reaffirmed a “market outperform” rating and issued a $24.00 price target on shares of Kura Oncology in a report on Monday, August 24th. Wall Street Zen upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Sanford C. Bernstein set a $24.00 price objective on Kura Oncology in a report on Monday, June 15th. Finally, Jefferies Financial Group set a $24.00 price objective on Kura Oncology in a research report on Thursday, May 28th.

Insider Activity at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of the company’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total transaction of $834,002.78. Following the completion of the transaction, the insider directly owned 182,345 shares in the company, valued at approximately $1,790,627.90. This represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Teresa Brophy Bair sold 31,487 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total transaction of $397,680.81. Following the transaction, the insider directly owned 195,444 shares in the company, valued at approximately $2,468,457.72. The trade was a 13.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 120,761 shares of company stock worth $1,283,346 over the last 90 days. 7.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of KURA. Dimensional Fund Advisors LP lifted its position in shares of Kura Oncology by 32.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock valued at $11,591,000 after acquiring an additional 348,127 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in Kura Oncology by 69.7% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 568,845 shares of the company’s stock valued at $6,240,000 after purchasing an additional 233,633 shares during the last quarter. UBS Group AG lifted its holdings in Kura Oncology by 118.3% in the 4th quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock valued at $11,014,000 after purchasing an additional 574,455 shares in the last quarter. Nan Fung Trinity HK Ltd. boosted its stake in Kura Oncology by 317.9% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 964,880 shares of the company’s stock worth $10,025,000 after purchasing an additional 734,000 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its stake in Kura Oncology by 285.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 158,850 shares of the company’s stock worth $1,291,000 after purchasing an additional 117,650 shares during the last quarter.

Kura Oncology Stock Performance

Shares of NASDAQ KURA opened at $12.66 on Friday. The company’s fifty day moving average price is $10.86 and its 200 day moving average price is $9.64. Kura Oncology has a 1 year low of $7.36 and a 1 year high of $13.90. The company has a market capitalization of $1.13 billion, a PE ratio of -3.76 and a beta of 0.38. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. The company had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $20.16 million. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. On average, research analysts predict that Kura Oncology will post -3.23 earnings per share for the current year.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.